



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref.: ISLL:CH:2022

Date: 10<sup>th</sup> August, 2022

**The President,  
Listing Compliance Department  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001**

**The Vice President,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051**

**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUB: OUTCOME OF BOARD MEETING**

Dear Sir,

Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations") please note that the Board of Directors in their meeting held on today i.e. 10<sup>th</sup> August, 2022, have considered and approved the following:-

1. Standalone and Consolidated Un-audited Financial Results of Ind-Swift Laboratories Limited for the quarter ended 30<sup>th</sup> June, 2022. These Financial results are limited reviewed by the Statutory Auditors of the Company. The Limited Review Report as Submitted by the Statutory Auditors is also enclosed along with the Unaudited Financial Results.
2. Reappointment of M/s Avishkar Singhal Chartered Accountants (Registration No. 017362N) as the Statutory Auditors of the Company for a second term of Five consecutive years as recommended by Audit Committee, Subject to the approval of the Shareholders of the Company.
3. Reappointment of and payment of remuneration to SH. N.R Munjal (DIN 00015096), Chairman & Managing Director of the company for a period of next five years w.e.f. 23rd March, 2023 as recommended by Nomination and Remuneration Committee, Subject to the approval of the Shareholders of the Company.
4. Reappointment of and payment of remuneration to Sh. Himanshu Jain (DIN 00014533), Joint Managing Director of the company for a period of next five years w.e.f. 23rd March, 2023 as recommended by Nomination and Remuneration Committee, Subject to the approval of the Shareholders of the Company.





# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



5. Reappointment of and payment of remuneration to Sh. Rishav Mehta (DIN 03028663), Executive Director of the company for a period of next five years w.e.f. 23rd March, 2023 as recommended by Nomination and Remuneration Committee, Subject to the approval of the Shareholders of the Company.
6. Payment of Remuneration to Sh. Sahil Munjal (Din 00015407), Executive Director of The Company, as recommended by Nomination and Remuneration Committee, Subject to the approval of the Shareholders of the Company.
7. To convene the 27<sup>th</sup> Annual General Meeting of the Members of the Company on Friday, the 30<sup>th</sup> day of September, 2022 at 11:30 A.M.
8. Closure of Register of members of the Company from Monday, the 26<sup>th</sup> day of September, 2022 to Friday, 30<sup>th</sup> September, 2022 (both days inclusive), for the purpose of Annual General Meeting of the Company.
9. The Board has approved the appointment of Mr. Vishal Arora, Practising Company Secretary as Scrutinizer to scrutinize the e-voting process in a fair and transparent manner in connection with the 27<sup>th</sup> Annual General Meeting.

Pursuant to the SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the brief profile of the Directors/ Auditors are enclosed herewith.

The un-audited financial results of the Company will also be available on the website of the Company i.e. [www.indswiftlabs.com](http://www.indswiftlabs.com).

The Board Meeting commenced at 03:00 P.M and concluded at 07:50 P.M.

You are requested to kindly take the same on record.

Thanking you,

**Certified True Copy**  
**For IND-SWIFT LABORATORIES LTD.**



**PARDEEP VERMA**  
**AVP-CORPORATE AFFAIRS &**  
**COMPANY SECRETARY**

Encl: As above



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LTD.				
Regd Office : S.C.O. 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101				
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH, JUNE 2022				
CIN L24232CH1995PLC015553				
Particulars	STANDALONE			
	Quarter Ended 30.06.2022	Quarter Ended 31.03.2022	Quarter Ended 30.06.2021	Year Ended 31.03.2022
	Unaudited	Audited	Unaudited	Audited
<b>Income from Operations:</b>				
Revenue from operations	27152.23	27581.87	24204.99	98809.00
Other Income	738.98	2063.54	636.79	4249.69
<b>Total Income</b>	<b>27891.21</b>	<b>29645.41</b>	<b>24841.78</b>	<b>103058.69</b>
<b>EXPENSES:</b>				
a. Cost of Materials Consumed	14671.46	15142.82	12361.10	53656.65
b. Purchase of stock in Trade	184.76	105.56	0.00	105.56
c. (Increase) / decrease in FG, WIP & stock in trade	(1095.29)	820.64	(215.74)	(3946.65)
d. Employee benefit	3316.92	2957.10	3119.84	12461.69
e. Finance Costs	2397.70	2349.49	2412.38	9554.50
f. Depreciation	1626.07	8177.81	1405.68	13096.95
g. Other expenditure	4775.74	5047.93	3875.57	17161.20
<b>TOTAL EXPENSES</b>	<b>25877.35</b>	<b>34601.34</b>	<b>22958.84</b>	<b>102089.90</b>
Profit/(loss) before exceptional items and Tax	2013.86	(4955.93)	1882.94	968.79
Exceptional items (Income) /loss	0.00	0.00	0.00	169.24
Profit/(loss) before Tax (After exceptional items)	2013.86	(4955.93)	1882.94	799.55
<b>Tax Expenses :-</b>				
Current Tax	0.00	496.11	0.00	496.11
Mat credit Utilisation	0.00	1887.76	0.00	1887.76
Deferred Tax	0.00	(1091.69)	0.00	(1091.69)
Income Tax Adjustment of Previous Years	0.00	70.53	7.77	78.30
Profit/ (Loss) after tax and before share of profit (loss) in Joint Venture	2013.86	(6318.63)	1875.17	(570.92)
Share of profit (loss) in joint venture	0.00	0.00	0.00	0.00
<b>Profit (+)/ Loss (-) for the period from continuing operations</b>	<b>2013.86</b>	<b>(6318.63)</b>	<b>1875.17</b>	<b>(570.92)</b>
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00
<b>Net Profit/ (Loss) for the period after tax &amp; Exceptional items</b>	<b>2013.86</b>	<b>(6318.63)</b>	<b>1875.17</b>	<b>(570.92)</b>
<b>Other Comprehensive Income</b>				
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00
B) Items that will be reclassified into P/L A/c	0.00	42.54	0.00	42.54
<b>Other Comprehensive Income ( Loss) for the period , net of Tax</b>	<b>0.00</b>	<b>42.54</b>	<b>0.00</b>	<b>42.54</b>
<b>Total Comprehensive Income for the Period</b>	<b>2013.86</b>	<b>(6361.17)</b>	<b>1875.17</b>	<b>(613.46)</b>
<b>Paid up Equity Share Capital (Face Value of Rs. 10/- per Share)</b>	<b>5908.69</b>	<b>5908.69</b>	<b>5908.69</b>	<b>5908.69</b>
<b>Reserve excluding revaluation reserves</b>				<b>37625.85</b>
<b>EPS (of Rs. 10/- each) (Not annualised)</b>				
Basic	3.41	(10.69)	3.17	(0.97)
Diluted	3.41	(10.69)	3.17	(0.97)

Place: Chandigarh  
 Date: 10.08.2022

for Ind-Swift Laboratories Limited

*N.R. Munjal*  
 N.R. Munjal  
 Chairman and Managing Director



# Avishkar Singhal & Associates

## CHARTERED ACCOUNTANTS

---

### LIMITED REVIEW

The Board of Directors  
Ind-Swift Laboratories Ltd  
SCO 850, NAC Manimajra  
Chandigarh

We have reviewed the accompanying statement of unaudited standalone financial results of Ind-Swift Laboratories Ltd. for the Quarter ended 30.06.2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Avishkar Singhal & Associates  
Chartered Accountants  
FRN: 017362N

  
(CA. Avishkar Singhal)  
Partner  
Mem. No. 098689



Place: Chandigarh  
Date: 10.08.2022  
UDIN: 22098689A0TIUG4135

S.C.O. 2413-14, IInd Floor, Sector – 22 C, Chandigarh-160022

Phone: 0172-5088885, E-mail: [avishkarsmail@gmail.com](mailto:avishkarsmail@gmail.com)

Mobile: 98146-02890, 98880-04461, 98146-12817



# Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
 CIN No. L24232CH1995PLC015553



IND- SWIFT LABORATORIES LTD.				
Regd Office : S.C.O. 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101				
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH, JUNE 2022				
CIN L24232CH1995PLC015553				
Rs. In Lacs				
Particulars	CONSOLIDATED			
	Quarter Ended 30.06.2022	Quarter Ended 31.03.2022	Quarter Ended 30.06.2021	Year Ended 31.03.2022
	Unaudited	Audited	Unaudited	Audited
<b>Income from Operations:</b>				
Revenue from operations	28016.83	30664.69	24980.20	103873.36
Other Income	739.00	2121.45	636.85	4349.55
<b>Total Income</b>	<b>28755.82</b>	<b>32786.14</b>	<b>25617.06</b>	<b>108222.91</b>
<b>EXPENSES:</b>				
a. Cost of Materials Consumed	15309.82	17806.81	12941.17	57583.95
b. Purchase of stock in Trade	184.76	105.56	0.00	105.56
c. (Increase) /decrease in FG,WIP & stock in trade	(1095.29)	820.64	(215.74)	(3946.65)
d. Employee benefit	3381.35	3015.24	3179.13	12709.16
e. Finance Costs	2397.70	2349.49	2412.38	9554.58
f. Depreciation	1627.80	8181.27	1405.68	13103.87
g. Other expenditure	4935.67	5246.77	3992.68	17859.20
<b>TOTAL EXPENSES</b>	<b>26741.80</b>	<b>37525.79</b>	<b>23715.31</b>	<b>106969.67</b>
<b>Profit(loss) before exceptional items and Tax</b>	<b>2014.03</b>	<b>(4739.65)</b>	<b>1901.75</b>	<b>1253.24</b>
Exceptional Items (Income) /loss	0.00	0.00	0.00	(0.00)
<b>Profit(loss) before Tax (After exceptional items)</b>	<b>2014.03</b>	<b>(4739.65)</b>	<b>1901.75</b>	<b>1253.24</b>
<b>Tax Expenses :-</b>				
Current Tax	22.34	539.07	13.57	593.78
Mat credit Utilisation	0.00	1887.76	0.00	1887.76
Deferred Tax	0.00	(1091.69)	0.00	(1091.69)
Income Tax Adjustment of Previous Years	0.00	70.53	7.77	78.30
<b>Profit/ (Loss) after tax and before share of profit (loss) in Joint Venture</b>	<b>1991.69</b>	<b>(6145.32)</b>	<b>1880.41</b>	<b>(214.90)</b>
Share of profit (loss) in joint venture	(3.75)	0.00	0.00	0.00
<b>Profit (+)/ Loss (-) for the period from continuing operations</b>	<b>1987.93</b>	<b>(6145.32)</b>	<b>1880.41</b>	<b>(214.90)</b>
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00
<b>Profit (+)/ Loss (-) from discontinuing operations(after Tax)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>Net Profit / ( Loss) for the period after tax &amp; Exceptional items)</b>	<b>1987.93</b>	<b>(6145.32)</b>	<b>1880.41</b>	<b>(214.90)</b>
<b>Other Comprehensive Income</b>				
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00
B) Items that will be reclassified into P/L A/c	0.00	42.54	0.00	42.54
<b>Other Comprehensive Income ( Loss) for the period , net of Tax</b>	<b>0.00</b>	<b>42.54</b>	<b>0.00</b>	<b>42.54</b>
<b>Total Comprehensive Income for the Period</b>	<b>1987.93</b>	<b>(6187.86)</b>	<b>1880.41</b>	<b>(257.44)</b>
<b>Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)</b>	<b>5908.69</b>	<b>5908.69</b>	<b>5908.69</b>	<b>5908.69</b>
<b>Reserve excluding revaluation reserves</b>				<b>34467.44</b>
<b>EPS (of Rs. 10/- each) (Not annualised)</b>				
Basic	3.36	(10.40)	3.18	(0.36)
Diluted	3.36	(10.40)	3.18	(0.36)

Place: Chandigarh  
 Date: 10.08.2022

for Ind- Swift Laboratories Limited

*N.R. Munjal*  
 N.R. Munjal  
 Chairman and Managing Director



# Avishkar Singhal & Associates

CHARTERED ACCOUNTANTS

---

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to date Financial Results of the company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.**

The Board of Directors  
Ind-Swift Laboratories Ltd  
SCO 850, NAC Manimajra  
Chandigarh

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Ind -Swift Laboratories Ltd. ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) before tax for the quarter ended 30.06.2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matter, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



S.C.O. 2413-14, IInd Floor, Sector – 22 C, Chandigarh-160022

Phone: 0172-5088885, E-mail: [avishkarsmail@gmail.com](mailto:avishkarsmail@gmail.com)

Mobile: 98146-02890, 98880-04461, 98146-12817

4) The Statement includes the results of:

Particulars	Name
Subsidiary Company	Ind Swift Laboratories Inc. USA Halcyon Life Sciences Pvt Ltd Fortune (India) Constructions Ltd
Joint Venture	INDIS Healthcare LLP M/s MJM Remedies Private Limited

- 5) Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6) The consolidated unaudited financial results includes the interim financial statements/financial information/financial results of three subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/financial information/financial results reflect total revenue of Rs 8.65 Crores, total net profit/(loss) before tax of Rs (0.22) crores and total comprehensive income/(loss) of Rs (0.22) Crores, for the quarter ended 30.06.2022 as considered in the consolidated unaudited financial results.
- 7) The consolidated unaudited financial results includes the interim financial statements/financial information/financial results of INDIS Healthcare LLP (Joint Venture) which have not been reviewed/audited by their auditors, whose interim financial statements/financial information/financial results reflect total net profit/(loss) of Rs.(0.03) crore. The second Joint Venture of the company, M/s MJM Remedies Private Limited has not commenced any operations yet. According to the information and explanations given to us by the Management, these interim financial statements/financial information/financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For Avishkar Singhal & Associates  
Chartered Accountants  
FRN: 017362N



(CA Avishkar Singhal)

Partner

Mem. No. 098689

Place: Chandigarh

Date: 10.08.2022

UDIN: 22098689AOTJFI1690



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



## Notes: -

1. During the quarter ended 30<sup>th</sup> June, 2022, Company has earned Standalone EBITDA of Rs 60.16 crores against EBITDA of Rs. 55.66 crores for the quarter ended 30<sup>th</sup> June, 2021. Standalone Net Profit for the current quarter is Rs. 20.14 crores as compared to Net Profit of Rs. 18.75 crores for corresponding quarter of previous year.
2. The un-audited standalone and consolidated financial results for the quarter ended June 30, 2022 in respect of Ind-Swift Laboratories Limited ('the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 10, 2022. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
3. The above is an extract of the detailed format of the standalone and consolidated unaudited financial results for the quarter ended 30<sup>th</sup> June, 2022 filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the full format of the standalone and consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2022 are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.indswiflabs.com.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. The consolidated financial results include the financial results of the parent company Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
  - a) Ind-Swift Laboratories Inc., USA
  - b) Fortune (India) Constructions Limited
  - c) Halcyon Life Sciences Private Limited
  - d) Indis Healthcare LLP (Joint Venture)Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.
6. No adjustment has been made in respect of Deferred Taxes & current Tax as per Ind-AS 12, as the same would be provided at year end.
7. Company's new joint venture, M/s MJM Remedies Private Limited has not commenced any operations yet.
8. The previous period figures have been re-grouped and re-arranged wherever necessary.





# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



9. The Company is exclusively in the Pharmaceutical Business segment.
10. Additional disclosures as per regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 are enclosed as Annexure-1.

For IND-SWIFT LABORATORIES LTD

N.R. Munjal  
Chairman and Managing Director



Place : Chandigarh  
Date : 10.08.2022



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



## Annexure-I

S.no.	Ratios As on	Qtr Ended 30-6-2022	Year Ended 31-3-2022	Qtr Ended 31.03.2022	Qtr Ended 30-6-2021
	Net Worth	45,620.29	43,606.43	43,606.43	43,237.15
1	Asset coverage of NCDs	1.91	1.89	1.89	1.93
2	Debt-Equity Ratios	2.04	2.16	2.16	2.24
3	Debt Service coverage Ratio	1.72	1.73	1.69	1.59
4	Interest Service Coverage Ratio	2.70	2.58	2.57	2.42
5	Current Ratio	3.03	3.19	3.19	3.20
6	Long term debt to working capital	1.17	1.22	1.22	1.44
7	Current Liability Ratio	0.19	0.17	0.17	0.24
8	Total Debts To Total Assets	0.51	0.52	0.52	0.53
9	Trade receivable turnover ratio	2.48	2.39	2.66	2.37
10	Inventory turnover ratio	2.55	2.57	2.87	2.68
11	Operating Profit Margin (%)	0.22	0.24	0.21	0.23
12	Net Profit Ratio (%)	7.42	-0.58	-22.91	1.94

*Handwritten signature*



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



**Details under Regulation 30 of Listing Regulations read with clause 7 of Annexure I of SEBI Circular dated September 9, 2015**

## **BRIEF PROFILE OF SHRI. NAVRATTAN MUNJAL CHAIRMAN & MANAGING DIRECTOR**

<b>Name of the Director</b>	Sh. Navrattan Munjal (DIN: 00015096)
<b>Date of re-appointment</b>	The Current term of Sh. Navrattan Munjal Chairman & Managing Director is going to expire on 22 <sup>nd</sup> March 2023. Sh. Navrattan Munjal has been proposed to be reappointed as Chairman & Managing Director of the Company for a period of next five year w.e.f 23 <sup>rd</sup> March 2023 subject to the approval of shareholder in ensuing Annual General meeting of the Company.
<b>Type</b>	Chairman & Managing Director
<b>Age</b>	70 Years
<b>Date of Appointment</b>	Re-appointment with effect from 23 <sup>rd</sup> March, 2023.
<b>Qualification</b>	Graduate
<b>Expertise</b>	Sh. N.R. Munjal, Chairman & Managing Director is a key part of the 35 years old Ind-Swift Group and more than 30 years of vast experience in the area of long term strategy formulation, leading and monitoring the senior management in implementation of Business plans for the company, Exploring new and innovative avenues for business growth of the group, Mentoring and ensuring the setting up of a conducive culture for the Company.
<b>Directorships held in other Companies</b>	IND SWIFT LIMITED NIMBUA GREENFIELD (PUNJAB) LIMITED ESSIX BIOSCIENCES LIMITED MOHALI GREEN ENVIRONMENT PRIVATE LIMITED
<b>No. of Equity Shares held in the Company</b>	9,20,724 equity shares of Rs. 10 each
<b>Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19</b>	Sh. Navrattan Munjal is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
<b>Relationship Between Directors/ KMP inter-se</b>	Sh. Navrattan Munjal is father of Mr. Sahil Munjal who is an Executive Director of the Company.



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



## BRIEF PROFILE OF MR. HIMANSHU JAIN JOINT MANAGING DIRECTOR

<b>Name of the Director</b>	Mr. Himanshu Jain (DIN: 00014533)
<b>Date of re-appointment</b>	The Current term of Mr. Himanshu Jain Joint Managing Director is going to expire on 22 <sup>nd</sup> March 2023. Mr. Himanshu Jain has been proposed to be reappointed as Joint Managing Director of the Company for a period of next five year w.e.f 23 <sup>rd</sup> March 2023 subject to the approval of shareholder in Ensuing Annual General meeting.
<b>Type</b>	Joint Managing Director
<b>Age</b>	40 Years
<b>Date of Appointment</b>	Re-appointment with effect from 23 <sup>rd</sup> March, 2023.
<b>Qualification</b>	Graduate
<b>Expertise</b>	Mr. Himanshu Jain, Jt. Managing Director, Ind-Swift Laboratories Ltd. is having more than 15 years' experience in pharmaceutical industry and project planning & control and taking care of all long term strategy in finance and accounts
<b>Directorships held in other Companies</b>	IND SWIFT LIMITED DASHMESH MEDICARE PRIVATE LIMITED ESSIX BIOSCIENCES LIMITED FORTUNE(INDIA)CONSTRUCTIONS LIMITED MJM REMEDIES PRIVATE LIMITED
<b>No. of Equity Shares held in the Company</b>	4,06,961 equity shares of Rs. 10 each
<b>Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19</b>	Mr. Himanshu Jain is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
<b>Relationship Between Directors/ KMP inter-se</b>	Mr. Himanshu Jain is not related to any other Director of the Company





# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



## BRIEF PROFILE OF MR. RISHAV MEHTA EXECUTIVE DIRECTOR

<b>Name of the Director</b>	Mr. Rishav Mehta (DIN: 00015407)
<b>Date of re-appointment</b>	The Current term of Mr. Rishav Mehta Executive Director is going to expire on 22 <sup>nd</sup> March 2023. Mr. Rishav Mehta has been proposed to be reappointed as Executive Director of the Company for a period of next five year w.e.f 23 <sup>rd</sup> March 2023 subject to the approval of shareholder in Ensuing Annual General meeting.
<b>Type</b>	Executive Director
<b>Age</b>	31 Years
<b>Date of Appointment</b>	Re-appointment with effect from 23 <sup>rd</sup> March, 2023.
<b>Qualification</b>	Graduate
<b>Expertise</b>	Mr. Rishav Mehta, Executive Director, Ind-Swift Laboratories Ltd. is having over eight years of experience in pharmaceutical industry, project planning & control. He is playing active role in production management and development of new generic products.
<b>Directorships held in other Companies</b>	IND SWIFT LIMITED DASHMESH MEDICARE PRIVATE LIMITED ESSIX BIOSCIENCES LIMITED VIBRANT AGRO INDUSTRIES LIMITED
<b>No. of Equity Shares held in the Company</b>	4,54,545 equity shares of Rs. 10 each
<b>Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19</b>	Mr. Rishav Mehta is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
<b>Relationship Between Directors/ KMP inter-se</b>	Mr. Rishav Mehta is not related to any other Director of the Company





# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



## BRIEF PROFILE OF M/S AVISHKAR SINGHAL & ASSOCIATES STATUTORY AUDITOR OF THE COMPANY

S No	Particulars	Details
1	<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	The first term of office of M/s Avishkar Singhal & Associates, Chartered Accountants, Statutory Auditors of the company is valid upto the ensuing Annual General Meeting of the Company. The Board of Directors of the Company at their meeting held today have approved the re-appointment of M/s Avishkar Singhal & Associates, as the statutory Auditors for a second term of 5 (Five) years.
2	<b>Date of appointment</b>	At the ensuing Annual General Meeting of the Company
3	<b>Term of appointment</b>	Subject to the approval of the Shareholders, re-appointed for the second term of five consecutive years commencing from the conclusion of ensuing 27 <sup>th</sup> Annual General Meeting of the Company, till the conclusion of the 32 <sup>nd</sup> Annual General Meeting of the Company to be held in the year 2027.
4	<b>Brief profile (in case of appointment)</b>	M/s Avishkar Singhal & Associates (Firm Registration No.:017362N) registered with the Institute of Chartered Accountants of India (ICAI) have more than 15 years of experience in Accounting Services, Tax Advisory & Management, Financial Management & Valuation, Company Law matters. The firm has been carrying out statutory audit of reputed listed Companies and carries a good professional track-record.

